HanchorBio Inc. (TPEx: 7827), a clinical-stage biotechnology firm focused on developing next-generation immunotherapies, has announced that it will present new clinical data related to HCB101 and preclinical findings for HCB301 at five significant international oncology congresses scheduled for the fourth quarter of 2025.
The presentations will cover advancements in HCB101, which includes data from the HCB101-101 monotherapy trial (NCT05892718) and the HCB101-201 combination study (NCT06771622). Additionally, preclinical results from HCB301, a tri-specific checkpoint immunotherapy, will also be highlighted, showcasing the company”s commitment to pioneering next-generation innate immune checkpoint therapies.
The following events will feature the HanchorBio presentations:
- Federation of Asian Clinical Oncology (FACO), October 24-25, 2025 – Two poster presentations showcasing HCB101 monotherapy and its use in combination with standard care for advanced cancers.
- Society for Immunotherapy of Cancer (SITC), November 5-9, 2025 – Two late-breaking poster presentations from HCB101-101 and HCB101-201 that will emphasize safety, pharmacology, and emerging efficacy signals, along with the first preclinical data from HCB301.
- ESMO Asia Congress, December 5-7, 2025 – An abstract will update results from HCB101-101, highlighting safety and activity across various solid tumors and hematologic malignancies.
- American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 – A poster presentation will cover the first-in-human Phase 1 study of HCB101 in patients with relapsed/refractory non-Hodgkin lymphoma.
- ESMO Immuno-Oncology Congress (ESMO-IO), December 10-12, 2025 – An abstract will integrate findings from both the HCB101 monotherapy and combination data across multiple solid tumor indications.
Dr. Scott Liu, Chairman, CEO, and Founder of HanchorBio, stated, “Presenting across five major oncology meetings in one quarter underscores both the breadth and pace of HCB101″s clinical progress. HCB101 continues to validate our differentiated approach to CD47-SIRPα blockade, while the first preclinical data from HCB301 showcase the innovation of our FBDBTM platform in advancing next-generation, multi-checkpoint therapies. Together, they highlight HanchorBio”s commitment to delivering transformative treatments for patients with difficult-to-treat cancers and advancing the next generation of immunotherapies.”
HCB101 is characterized as a 3.5th-generation, affinity-optimized SIRPα-Fc fusion protein featuring an intact IgG4 Fc backbone, developed through HanchorBio”s proprietary FBDBTM platform. It is designed for selective CD47 targeting with minimal red blood cell binding, which helps avoid the anemia and thrombocytopenia commonly associated with earlier anti-CD47 monoclonal antibodies, while maintaining strong antibody-dependent cellular phagocytosis (ADCP) and bridging innate to adaptive immunity.
Key differentiators of HCB101 include an enhanced safety profile, robust immune activation, broad tumor applicability, and promising clinical translation, demonstrating durable disease control in various cancers. Meanwhile, HCB301 is designed to synergistically integrate three mechanisms into a single molecule—CD47-SIRPα blockade, PD-1 inhibition, and TGF-b pathway suppression—aimed at improving the tumor microenvironment.
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global biotechnology company specializing in immuno-oncology. The experienced team at HanchorBio has a proven history in biologics discovery and global development, striving to innovate cancer therapies that reactivate the immune system against diseases. The proprietary FBDBTM platform allows the creation of unique biologics targeting multiple pathways, addressing the challenges posed by existing anti-PD1/L1 therapies.
For more information, please visit www.HanchorBio.com.
